What is the recommended first-line treatment for a patient with non‑small cell lung cancer (NSCLC) harboring an activating EGFR mutation?

First-Line Treatment for EGFR-Mutant NSCLC

For patients with NSCLC harboring activating EGFR mutations (exon 19 deletions or L858R), osimertinib is the preferred first-line treatment, with combination strategies (osimertinib plus chemotherapy or amivantamab-based regimens) reserved for high-risk patients with CNS metastases, high tumor burden, or elevated ctDNA. 1, 2

Standard First-Line Approach

Preferred Option: Osimertinib Monotherapy

• Osimertinib is the category 1 preferred treatment for patients with common EGFR mutations (exon 19 deletions or L858R) regardless of performance status (PS 0-4) 1, 3
• Median PFS: 18.9 months vs 10.2 months compared to first-generation TKIs 1
• Median OS: 38.6 months vs 31.8 months compared to erlotinib/gefitinib 1
• Superior CNS penetration and efficacy compared to earlier generation TKIs 3

Alternative Single-Agent Options

Other acceptable first-line options include 1, 2:

• Erlotinib (category 1)
• Gefitinib (category 1)
• Afatinib (category 1)
• Dacomitinib

These are appropriate when osimertinib is unavailable or not tolerated, though they are generally considered inferior to osimertinib 3.

Treatment Intensification for High-Risk Patients

Combination Regimens (Category 1)

Osimertinib + Chemotherapy (FLAURA2 regimen):

• Osimertinib plus pemetrexed and platinum (cisplatin or carboplatin) 1
• Median PFS: 25.5 months vs 16.7 months (osimertinib alone) 1
• Indication: Consider for patients with high tumor burden, CNS metastases, or aggressive disease biology
• Caveat: Higher grade 3+ adverse events (primarily chemotherapy-related) 1

Amivantamab-based combinations:

• Amivantamab plus lazertinib (MARIPOSA regimen) 2
• Key benefit: Improved intracranial PFS (HR 0.55) 2
• Important: Subcutaneous formulation reduces infusion-related reactions compared to IV administration

Other Combination Options

• Erlotinib plus bevacizumab (for nonsquamous histology without recent hemoptysis) 1
• Erlotinib plus ramucirumab 1

Risk Stratification Algorithm

High-Risk Features Favoring Combination Therapy:

• CNS metastases at baseline (especially multiple or symptomatic lesions)
• Liver metastases
• High tumor burden (multiple sites, bulky disease)
• Elevated baseline ctDNA levels
• TP53 co-mutations (prognostic but not definitively predictive)

Standard-Risk Features Favoring Osimertinib Monotherapy:

• Limited metastatic sites
• Good performance status (PS 0-1)
• No CNS involvement
• Lower disease burden

Critical Performance Status Considerations

• PS 0-2: All treatment options appropriate 4
• PS 3-4: EGFR TKIs (particularly osimertinib) may still be offered as they are better tolerated than chemotherapy 4
• Poor PS patients should NOT receive chemotherapy-based combinations 4

Important Clinical Pitfalls

Avoid These Common Errors:

1. Do NOT use immune checkpoint inhibitors as first-line therapy in EGFR-mutant NSCLC - they are less effective regardless of PD-L1 expression 1

2. Do NOT combine pembrolizumab with chemotherapy in EGFR-mutant disease - no OS or PFS benefit demonstrated 1

3. Be cautious with ICI-to-TKI sequencing - long half-life of ICIs may increase toxicity when transitioning to osimertinib 1

4. Test for EGFR mutations BEFORE starting any systemic therapy - chemotherapy first-line is inferior in mutation-positive patients 5

Treatment Beyond Progression

Oligoprogression Strategy:

• Continue EGFR TKI with local ablative therapy (surgery, SBRT, SRS) for isolated progression sites 4, 6, 3
• Particularly effective for CNS oligoprogression

Systemic Progression:

• Rebiopsy to identify resistance mechanisms (T790M, MET amplification, SCLC transformation) 3
• Second-line options depend on resistance mechanism and prior therapy

Practical Treatment Selection Framework

Step 1: Confirm EGFR mutation status (exon 19 deletion or L858R)

Step 2: Assess risk factors:

• CNS metastases present? → Consider combination therapy
• High tumor burden or liver metastases? → Consider combination therapy
• PS 3-4? → Osimertinib monotherapy only

Step 3: Evaluate patient factors:

• Can tolerate chemotherapy toxicity? → Combination eligible
• Logistical barriers to frequent visits? → Favor monotherapy
• Patient preference after shared decision-making

Step 4: Select regimen:

• Standard risk: Osimertinib monotherapy
• High risk with good PS: Osimertinib + chemotherapy OR amivantamab + lazertinib
• Poor PS (3-4): Osimertinib monotherapy

The evidence strongly supports osimertinib as the backbone of first-line therapy, with the decision to intensify treatment based on individual risk stratification rather than universal application of combination regimens 1, 2, 3.